Joshua Brumm
2022 - Dyne Therapeutics
In 2022, Joshua Brumm earned a total compensation of $4.3M as President and Chief Executive Officer at Dyne Therapeutics, a 6% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $335,500 |
|---|---|
| Option Awards | $1,661,236 |
| Salary | $610,000 |
| Stock Awards | $1,709,371 |
| Other | $996 |
| Total | $4,317,103 |
Brumm received $1.7M in stock awards, accounting for 40% of the total pay in 2022.
Brumm also received $335.5K in non-equity incentive plan, $1.7M in option awards, $610K in salary and $996 in other compensation.
Rankings
In 2022, Joshua Brumm's compensation ranked 776th out of 5,625 executives tracked by ExecPay. In other words, Brumm earned more than 86.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 776 out of 5,625 | 86th |
Division Manufacturing | 350 out of 3,053 | 89th |
Major group Chemicals And Allied Products | 114 out of 1,380 | 92nd |
Industry group Drugs | 101 out of 1,281 | 92nd |
Industry Pharmaceutical Preparations | 74 out of 927 | 92nd |
Source: SEC filing on April 7, 2023.
Brumm's colleagues
We found three more compensation records of executives who worked with Joshua Brumm at Dyne Therapeutics in 2022.
News
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021
Kaleido Biosciences CEO Alison Lawton's 2019 pay falls 57% to $2.9M
May 8, 2020